Different disease progression patterns based on RECIST and CA-125 criteria and the impact on prognosis in patients with ovarian cancer treated with PARP inhibitors.

被引：0
|
作者：
Song, Kun [1 ]
Ma, Yana [1 ]
Bu, Hualei [1 ]
Zhang, Yawen [1 ]
机构：
[1] Shandong Univ, Qilu Hosp, Jinan, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17536
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A modified CA-125 progression criterion in ovarian cancer (OC) patients (pts) receiving maintenance treatment following complete clinical response (cCR) to primary therapy.
    Liu, P.
    Moon, J.
    Alberts, D. S.
    Monk, B. J.
    Brady, M.
    Markman, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 275S - 275S
  • [42] Prognostic and predictive significance of CA-125 elimination rate constant K (KELIM) in ovarian cancer patients treated with neoadjuvant chemotherapy in a real-world setting.
    Liontos, Michael
    Papatheodoridi, Alkistis
    Kunadis, Elena
    Svarna, Anna
    Theofanakis, Charalampos
    Fiste, Oraianthi
    Rouvali, Angeliki
    Goula, Kalliroi
    Markellos, Christos
    Andrikopoulou, Angeliki
    Potiri, Eirini
    Papanota, Aristea-Maria
    Kaparelou, Maria
    Koutsoukos, Konstantinos
    Thomakos, Nikolaos
    Haidopoulos, Dimitrios
    Rodolakis, Alexandros
    Zagouri, Flora
    You, Benoit
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] CORRELATION BETWEEN GCIG-CA125 AND RADIOLOGICAL PROGRESSION IN DETERMINING DISEASE PROGRESSION IN PATIENTS RECEIVING BEVACIZUMAB FOR ADVANCED OVARIAN CANCER: A RETROSPECTIVE STUDY.
    Giovannoni, S.
    Marchetti, C.
    Al Bakir, M.
    Luvero, D.
    Angioli, R.
    Kristeleit, R.
    McCormack, M.
    Panici, P. Benedetti
    Ledermann, J. A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 435 - 435
  • [44] ASSOCIATION BETWEEN PRETREATMENT CA-125 LEVELS AND SURGICALLY DOCUMENTED COMPLETE RESPONSES IN PATIENTS WITH OVARIAN-CANCER TREATED WITH 2ND-LINE INTRAPERITONEAL THERAPY
    MARKMAN, M
    REICHMAN, B
    HAKES, T
    CURTIN, J
    BARAKAT, R
    RUBIN, S
    JONES, W
    LEWIS, JL
    ALMADRONES, L
    HOSKINS, W
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1992, 118 (05) : 391 - 394
  • [45] CORRELATION OF CEA AND CA-125 SERUM LEVELS WITH THE PRESENCE OR ABSENCE OF DISEASE, RESPONSE TO CHEMOTHERAPY AND THE 2ND LOOK FINDINGS IN OVARIAN-CANCER PATIENTS
    BAFALOUKOS, D
    SIDIS, DP
    DIMITRIADIS, M
    TRAPALI, X
    LAFI, A
    KOUTSIOUBA, P
    ATHANASIOU, A
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1988, 14 (5-6): : 323 - 323
  • [46] Prognostic impact of progression type by RECIST criteria in patients with metastatic pancreatic cancer who received first-line gemcitabine-based chemotherapy
    Lee, J.
    Lee, M. A.
    Kim, I-H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [47] The impact of percent reduction in CA-125 levels on prediction of the extent of interval cytoreduction and outcome in patients with advanced stage cancer of mullerian origin treated with neoadjuvant chemotherapy
    Mahdi, H.
    Maurer, K.
    Nutter, B.
    Rose, P. G.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 44 - +
  • [48] Patterns of disease progression in advanced non-small cell lung cancer patients treated with PD-1 inhibitors
    Qin, Angel
    Kalemkerian, Gregory Peter
    Schneider, Bryan J.
    Hassan, Khaled Aref
    Cease, Kemp Bailey
    Zhao, Lili
    Warren, Edus H.
    Ramnath, Nithya
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] The impact of chemosensitivity assessed by modeled CA-125 KELIM on the likelihood of long progression-free survivorship (PS) after 1st line treatment in ovarian cancer: An analysis of 4,450 patients
    You, B.
    Van Wagensveld, L.
    Tod, M.
    Sonke, G. S.
    Kruitwagen, R.
    du Bois, A.
    Selle, F.
    Perren, T. J.
    Pfisterer, J.
    Joly, F.
    Cook, A.
    Kaminsky-Forrett, M-C.
    Wollschlaeger, K.
    Lortholary, A.
    Tome, O.
    Leary, A.
    Freyer, G.
    Van der Aa, M.
    Colomban, O.
    ANNALS OF ONCOLOGY, 2020, 31 : S616 - S616
  • [50] Focused Plenary Monitoring minimal residual disease using circulating tumor DNA in patients treated long-term with PARP inhibitors for ovarian cancer
    Lee, Dahye
    Kim, Yoo-Na
    Won, Dongju
    Lee, Jung-Yun
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S33 - S34
12345